Pneumologie 2017; 71(S 01): S1-S125
DOI: 10.1055/s-0037-1598376
Posterbegehung – Sektion Klinische Pneumologie
Asthma bronchiale – Stephanie Korn/Mainz, Christian Geßner/Leipzig
Georg Thieme Verlag KG Stuttgart · New York

Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)

D Hinds
1  Worldwide Epidemiology, GlaxoSmithKline, Collegeville, Pennsylvania
KR Chapman
2  University of Toronto, Toronto
P Piazza
3  Dock Family Medical Practice, Five Dock
M Gibbs
4  Global Respiratory Franchise, GlaxoSmithKline, Brentford
C Raherison
5  Bordeaux University
K Gaalswyk
6  Abt Srbi, Silver Spring, Maryland
T Greulich
7  Philipps-Universtät Marburg
J Lin
8  China-Japan Friendship Hospital, Beijing
M Adachi
9  International University of Health and Welfare, Tokyo
K Davis
1  Worldwide Epidemiology, GlaxoSmithKline, Collegeville, Pennsylvania
› Institutsangaben
Weitere Informationen


23. Februar 2017 (online)



Asthma treatments and guidelines change and can vary by country. Guidelines include the option to prescribe a single inhaled corticosteroid and long-acting ß-agonist fixed dose combination (ICS/LABA) as both a maintenance and reliever medication (SMART) with low dose ICS/formoterol as a reliever rather than a short-acting ß-agonist (SABA) for patients requiring low dose ICS/LABA treatment. GAPS aimed to describe physician perceptions and behaviors regarding asthma management in 6 countries.


1809 physicians seeing ≥4 adult asthma patients/month in Australia, Japan, China, Canada, France and Germany were surveyed (n≈300/country). Standardized questionnaires on asthma management were administered from 05 – 09/2015. Statistics were weighted to account for the sampling scheme.


Physicians generally (71%) estimated that most of their asthma patients were prescribed maintenance medication. Most physicians monitored adherence to maintenance medications (87% overall). Few patients received written asthma action plans (37%) and technology (i.e. mobile apps) was seldom used (15%). Physicians did not utilize validated patient reported questionnaires (10% overall) to assess asthma control, instead utilizing asthma symptoms, exacerbations and lung function measurements. 72% (n = 1286) had prescribed SMART and reported their SMART information source was from conferences (54%) or sales representatives (49%) rather than from guidelines. Almost all (91%) of the physicians who prescribed SMART co-prescribed a separate SABA reliever. 32% reported not writing anything different than the standard maintenance dosing instructions on a prescription for ICS/LABA.


Asthma management practices vary by country. Despite physicians' interest in SMART, the strategy is misunderstood, rarely being prescribed as outlined in randomized trial or guideline descriptions. Better education is needed, tailored to the healthcare system and physicians' preferences.

Abstract previously presented at ATS 2016, A1708.